Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov:88:106928.
doi: 10.1016/j.intimp.2020.106928. Epub 2020 Aug 24.

Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine

Rasoul Mirzaei  1 , Rokhsareh Mohammadzadeh  2 , Farzad Mahdavi  3 , Fariba Badrzadeh  4 , Sheida Kazemi  5 , Mehdi Ebrahimi  6 , Fatemeh Soltani  7 , Sima Kazemi  8 , Ali Salimi Jeda  9 , Mohammad Darvishmotevalli  10 , Rasoul Yousefimashouf  8 , Hossein Keyvani  11 , Sajad Karampoor  12
Affiliations
Review

Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine

Rasoul Mirzaei et al. Int Immunopharmacol. 2020 Nov.

Abstract

Coronavirus disease 2019 (COVID-19) is a pandemic infectious disease caused by the novel coronavirus called SARS-CoV-2. There is a gap in our understanding regarding the immunopathogenesis of COVID-19. However, many clinical trials are underway across the world for screening effective drugs against COVID-19. Nevertheless, currently, no proven effective therapies for this virus exists. The vaccines are deemed as a significant part of disease prevention for emerging viral diseases, since, in several cases, other therapeutic choices are limited or non-existent, or that diseases result in such an accelerated clinical worsening that the efficacy of treatments is restricted. Therefore, effective vaccines against COVID-19 are urgently required to overcome the tremendous burden of mortality and morbidity correlated with SARS-CoV-2. In this review, we will describe the latest evidence regarding outstanding vaccine approaches and the challenges for vaccine production.

Keywords: COVID-19; Immunopathogenesis; SARS-CoV-2; Vaccines.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Nothing declared.

Figures

Fig. 1
Fig. 1
The SARS-CoV-2 immunopathogenesis in the lung.
Fig. 2
Fig. 2
The current approaches considered for SARS-CoV-2.
Fig. 3
Fig. 3
The current ongoing clinical trial for candidate SARS-CoV-2 vaccines.
See this image and copyright information in PMC

References

    1. Lai C.C., Shih T.P., Ko W.C., Tang H.J., Hsueh P.R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int. J. Antimicrob. Agents. 2020;55(3) - PMC - PubMed
    1. Li H., Liu S.-M., Yu X.-H., Tang S.-L., Tang C.-K. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int. J. Antimicrob. Agents. 2020;55(5) - PMC - PubMed
    1. T.W.H. Organization, Coronavirus disease (COVID-19) pandemic, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
    1. Tang X., Wu C., Li X., Song Y., Yao X., Wu X., Duan Y., Zhang H., Wang Y., Qian Z., Cui J., Lu J. On the origin and continuing evolution of SARS-CoV-2. Natl. Sci. Rev. 2020 - PMC - PubMed
    1. Parvin F., Islam S., Urmy Z., Ahmed S. The symptoms, contagious process, prevention and post treatment of COVID-19. Europ. J. Physiotherapy Rehabilit. Stud. 2020